Carregant...
TRIB2 contributes to cisplatin resistance in small cell lung cancer
Small cell lung cancer (SCLC) is the most aggressive lung-cancer subtype and so far, no favorable therapeutic strategy has been established for chemo-resistant SCLC. Cisplatin is one of the most important components among all standard poly-chemotherapeutic regimens for SCLC; therefore, this study fo...
Guardat en:
| Publicat a: | Oncotarget |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Impact Journals LLC
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5752545/ https://ncbi.nlm.nih.gov/pubmed/29312632 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22741 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|